FIGURE

Fig. 3

ID

ZDB-FIG-180919-4

Publication

Zhang et al., 2018 - Monitoring antiangiogenesis of bevacizumab in zebrafish

Other Figures

All Figure Page

Back to All Figure Page

Fig. 3

Bevacizumab causes specific vasculature formation defects in the SIV.
(A–D) Representative fluorescent images of zebrafish embryos at 3 dpf treated with PBS (control) or bevacizumab (2 mg/mL). (A, B) In contrast, treatment with bevacizumab at the pectoral fin stage (2.5 dpf) causes specific vasculature formation defects in the SIV (B, white arrow). (C–D) Truncal vasculature of the zebrafish shows no appreciable phenotypic differences relative to control.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Drug Des Devel Ther